NASDAQ · Biotechnology

ENVB (ENVB) Stock

$1.34 +3.88% NASDAQ: ENVB Healthcare

Valuation

MetricValue
Price$1.34
Market Cap$799996
P/E Ratio-0.04
P/B Ratio0.56
P/S Ratio0.00
EPS (TTM)$-36.24
52-Week High$17.64
52-Week Low$1.26
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-183.11%
ROA-96.72%
ROCE-225.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio5.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-26.0M$-20.0M$-16.0M$-10.0M$-9.0M
Net Profit$-49.0M$-19.0M$0$-10.0M$-12.0M
EPS$-1244.28$-156.00$-97.08$-228.48$-36.24
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$27.0M$20.0M$4.0M$3.0M$5.0M
Total Liabilities$4.0M$4.0M$2.0M$1.0M$1.0M
Cash$17.0M$18.0M$2.0M$2.0M$5.0M
Borrowings$0$0$0$0$0

Latest News

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit Business Wire · Jun 29, 2026 Enveric Biosciences Announces Participation in 2026 BIO International Convention Business Wire · Jun 16, 2026 Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day Business Wire · Jun 9, 2026 Enveric Biosciences Begins Genotoxicity Testing for EB-003 MT Newswires · Jun 2, 2026 Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 Business Wire · Jun 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-17.0M$-14.0M$-8.0M$-8.0M
Investing Cash Flow$1.0M$-1.0M$0$0$0
Financing Cash Flow$3.0M$1.0M$0$5.0M$0
Net Cash Flow$16.0M$0$-15.0M$0$2.0M
Free Cash Flow$-12.0M$-18.0M$-14.0M$-8.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-0.09
FCF Yield-891.07%
Quick Ratio11.67
Interest Coverage—
Return 1Y-91.06%
Return 3Y-99.98%
Return 5Y-100.00%

Ownership

Insiders Held10.81%
Institutions Held2.86%
Institutions Float Held3.21%
Institutional HolderSharesReport Date
Geode Capital Management, LLC32,1492026-03-31
AdvisorShares Investments, LLC16,9742026-03-31
UBS Group AG3,6122026-03-31
Farther Finance Advisors, Llc3,0002026-06-30
Tower Research Capital LLC (TRC)1,1032026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AZTR $0.14 +0.80% -0.09 $1.49M 0.00%
HEPAHepion Pharmaceuticals, Inc. $0.05 +17.78% -0.21 $617116 0.00%
INDP $1.39 -3.82% -0.06 $2.43M 0.00%
JSPR $0.63 +1.48% -0.21 $10.24M 0.00%
ONCO $0.81 -1.89% -0.02 $270931 0.00%

About ENVB

ENVB is led by CEO Joseph Edward Tucker, employs 5 people, headquartered in US, publicly traded since 2015.

ENVB stock trades at $1.34 with a market capitalization of $799996. The stock is valued at a price-to-earnings (P/E) ratio of -0.04, price-to-book of 0.56, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.26 and $17.64, and currently trades 92.4% below its 52-week high.

On profitability, ENVB generates a return on equity (ROE) of -183.11%, return on capital employed of -225.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides